Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.06. | Bulletin from the annual general meeting in Biosergen AB (publ) | 1 | Cision News | ||
21.05. | Biosergen AB: Biosergen publishes interim report for the first quarter 2025 | 85 | GlobeNewswire (Europe) | May 21, 2025: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for first quarter 2025. The interim report is available as an attached document and on the company website... ► Artikel lesen | |
09.05. | Notice of annual general meeting in Biosergen AB | 1 | Cision News | ||
09.05. | BIOSERGEN AB: Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives | 1 | Cision News | ||
09.05. | BIOSERGEN AB: Biosergen takes aim at climate-driven fungal infections | 3 | Cision News | ||
BIOSERGEN Aktie jetzt für 0€ handeln | |||||
30.04. | BIOSERGEN AB: Biosergen publishes 2024 annual report | 1 | Cision News | ||
07.03. | BIOSERGEN AB: Biosergen scales up for future wins | 3 | Cision News | ||
05.03. | BIOSERGEN AB: Biosergen publishes interim report for fourth quarter 2024 | 2 | Cision News | ||
07.02. | BIOSERGEN AB: Biosergen's CEO: "These findings open up new possibilities" | 3 | Cision News | ||
04.02. | BIOSERGEN AB: Biosergen Successfully Completes Second Cohort of BSG005 Clinical Trial, Gaining Conclusive Proof-of-Concept Data, and Confirms 2025 Objectives | 1 | Cision News | ||
08.11.24 | Biosergen AB: Biosergen publishes interim report for third quarter 2024 | 125 | GlobeNewswire (Europe) | Friday November 8, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the... ► Artikel lesen | |
07.10.24 | Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial | 140 | GlobeNewswire (Europe) | October 7, 2024 - Biosergen AB ("Biosergen"), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |